Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers

Neuropsychopharmacology

Volumn 41, Issue 7, 2016, Pages 1742-1750

  Mick, Inge ^a   Myers, Jim ^a   Ramos, Anna C ^a,b   Stokes, Paul R A ^a,c   Erritzoe, David ^a   Colasanti, Alessandro ^a,c,d   Gunn, Roger N ^a,d   Rabiner, Eugenii A ^c,d   Searle, Graham E ^d   Waldman, Adam D ^a   Parkin, Mark C ^c   Brailsford, Alan D ^c   Galduróz, José C F ^b   Bowden Jones, Henrietta ^e   Clark, Luke ^f   Nutt, David J ^a   Lingford Hughes, Anne R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Imanova Ltd   (United Kingdom)

^e CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; CARFENTANIL C 11; ENDORPHIN; MU OPIATE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CARBON; CARFENTANIL; CENTRAL STIMULANT AGENT; FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMPULSIVENESS; MALE; PATHOLOGICAL GAMBLING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANCE ABUSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; DIAGNOSTIC IMAGING; GAMBLING; IMAGE PROCESSING; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINE; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; CARBON ISOTOPES; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; FENTANYL; GAMBLING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84949257490     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.340     Document Type: Article

References (53)

1. Bartley CA, Bloch MH (2013). Meta-analysis: pharmacological treatment of pathological gambling. Expert Rev Neurother 13: 887-894.
2. Blaszczynski APW, Simon W, McConaghy Neil (1986). Plasma endorphin levels in pathological gambling. J Gambl Behav 2: 3-14.
3. Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA et al (2013). In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [C]-(+)-PHNO. Mol Psychiatry 19: 1305-1313.
4. Bourdy R, Barrot M (2012). A new control center for dopaminergic systems: pulling the VTA by the tail. Trends Neurosci 35: 681-690.
5. Bowden-Jones H, Clark L (2011). Pathological gambling: a neurobiological and clinical update. Br J Psychiatry 199: 87-89.
6. Clark L, Limbrick-Oldfield EH (2013). Disordered gambling: a behavioral addiction. Curr Opin Neurobiol 23: 655-659.
7. Clark L, Stokes PR, Wu K, Michalczuk R, Benecke A, Watson BJ et al (2012). Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage 63: 40-46.
8. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D et al (2012). Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry 72: 371-377.
9. Cowlishaw S, Merkouris S, Dowling N, Anderson C, Jackson A, Thomas S (2012). Psychological therapies for pathological and problem gambling. Cochrane Database Syst Rev 11: CD008937.
10. Cyders MA, Smith GT, Spillane NS, Fischer S, Annus AM, Peterson C (2007). Integration of impulsivity and positive mood to predict risky behavior: development and validation of a measure of positive urgency. Psychol Assess 19: 107-118.
11. Doron R, Fridman L, Yadid G (2006). Dopamine-2 receptors in the arcuate nucleus modulate cocaine-seeking behavior. Neuroreport 17: 1633-1636.
12. Erritzoe D, Tziortzi A, Bargiela D, Colasanti A, Searle GE, Gunn RN et al (2014). In vivo imaging of cerebral dopamine D3 receptors in alcoholism. Neuropsychopharmacology 39: 1703-1712.
13. Ferris J, Wynne H (2001). Canadian Problem Gambling Index. Canadian Centre on Substance Abuse: Ottawa, Ontario.
14. Fethney J (2010). Statistical and clinical significance, and how to use confidence intervals to help interpret both. Aust Crit Care 23: 93-97.
15. Forbush KT, Shaw M, Graeber MA, Hovick L, Meyer VJ, Moser DJ et al (2008). Neuropsychological characteristics and personality traits in pathological gambling. CNS Spectr 13: 306-315.
16. Fuentes D, Tavares H, Artes R, Gorenstein C (2006). Self-reported and neuropsychological measures of impulsivity in pathological gambling. J Int Neuropsychol Soc 12: 907-912.
17. Ghitza UE, Preston KL, Epstein DH, Kuwabara H, Endres CJ, Bencherif B et al (2010). Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry 68: 697-703.
18. Gianoulakis C (1996). Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol 31 Suppl 1: 33-42.
19. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M et al (2005). Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 57: 1573-1582.
20. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino ML et al (2008). Brain mu-opioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology 200: 475-486.
21. Grant JE, Kim SW, Hollander E, Potenza MN (2008). Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology 200: 521-527.
22. Grant JE, Odlaug BL, Schreiber LR (2014). Pharmacological treatments in pathological gambling. Br J Clin Pharmacol 77: 375-381.
23. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G et al (2005). Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62: 57-64.
24. Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V et al (2009). Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a testretest study in healthy subjects. Eur J Nucl Med Mol Imaging 36: 275-286.
25. Hodgins DC, Stea JN, Grant JE (2011). Gambling disorders. Lancet 378: 1874-1884.
26. Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
27. Lingford-Hughes AR, Welch S, Peters L, Nutt DJ (2012). BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 26: 899-952.
28. Love TM, Stohler CS, Zubieta JK (2009). Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry 66: 1124-1134.
29. Lubman DI, Allen NB, Peters LA, Deakin JF (2008). Electrophysiological evidence that drug cues have greater salience than other affective stimuli in opiate addiction. J Psychopharmacol 22: 836-842.
30. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988). Anatomy of CNS opioid receptors. TrendsNeurosci 11: 308-314.
31. Meyer G, Schwertfeger J, Exton MS, Janssen OE, Knapp W, Stadler MA et al (2004). Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology 29: 1272-1280.
32. Michalczuk R, Bowden-Jones H, Verdejo-Garcia A, Clark L (2011). Impulsivity and cognitive distortions in pathological gamblers attending the UK National Problem Gambling Clinic: a preliminary report. Psychol Med 41: 2625-2635.
33. Mick I, Myers J, Stokes PR, Erritzoe D, Colasanti A, Bowden-Jones H et al (2014). Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. Int J Neuropsychopharmacol 17: 2069-2074.
34. Petrovic P, Pleger B, Seymour B, Kloppel S, De Martino B, Critchley H et al (2008). Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 28: 10509-10516.
35. Potenza MN (2008). Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos TransR Soc Lond B Biol Sci 363: 3181-3189.
36. Shaffer HJ, Labrie R, Scanlan KM, Cummings TN (1994). Pathological gambling among adolescents: Massachusetts Gambling Screen (MAGS). J Gambl Stud 10: 339-362.
37. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 Suppl 20: 22-33.
38. Shinohara K, Yanagisawa A, Kagota Y, Gomi A, Nemoto K, Moriya E et al (1999). Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate. Appl Human Sci 18: 37-42.
39. Soderman AR, Unterwald EM (2009). Cocaine-induced mu opioid receptor occupancy within the striatum is mediated by dopamine D2 receptors. Brain Res 1296: 63-71.
40. Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM (2000). Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem 43: 381-391.
41. Titeler M, Lyon RA, Kuhar MJ, Frost JF, Dannals RF, Leonhardt S et al (1989). Mu opiate receptors are selectively labelled by [3H] carfentanil in human and rat brain. Eur J Pharmacol 167: 221-228.
42. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al (2011). Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
43. Ulm RR, Volpicelli JR, Volpicelli LA (1995). Opiates and alcohol self-administration in animals. J Clin Psychiatry 56 Suppl 7: 5-14.
44. van Holst RJ, van den Brink W, Veltman DJ, Goudriaan AE (2010). Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev 34: 87-107.
45. Van Kammen DP, Murphy DL (1975). Attenuation of the euphoriant and activating effects of d-and l-amphetamine by lithium carbonate treatment. Psychopharmacologia 44: 215-224.
46. Verdejo-Garcia A, Lawrence AJ, Clark L (2008). Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 32: 777-810.
47. Votinov M, Pripfl J, Windischberger C, Kalcher K, Zimprich A, Zimprich F et al (2014). A genetic polymorphism of the endogenous opioid dynorphin modulates monetary reward anticipation in the corticostriatal loop. PLoS One 9: e89954.
48. Whiteside SP, Lynam DR (2001). The Five Factor Model and impulsivity: using a structural model of personality to understand impulsivity. Pers Individ Dif 30: 669-689.
49. Williams TM, Daglish MR, Lingford-Hughes A, Taylor LG, Hammers A, Brooks DJ et al (2007). Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. Br J Psychiatry 191: 63-69.
50. Williams TM, Davies SJ, Taylor LG, Daglish MR, Hammers A, Brooks DJ et al (2009). Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol 19: 740-748.
51. Young MM, Wohl MJ (2009). The Gambling Craving Scale: psychometric validation and behavioral outcomes. Psychol Addict Behav 23: 512-522.
52. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ (1996). Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2: 1225-1229.
53. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA et al (2003). Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60: 1145-1153.